###begin article-title 0
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
Metalloproteinase regulation improves in vitro generation of efficacious platelets from mouse embryonic stem cells
###end article-title 0
###begin p 1
###xml 25 47 25 47 <email xmlns:xlink="http://www.w3.org/1999/xlink">keto@ims.u-tokyo.ac.jp</email>
###xml 71 97 71 97 <email xmlns:xlink="http://www.w3.org/1999/xlink">nakauchi@ims.u-tokyo.ac.jp</email>
CORRESPONDENCE Koji Eto: keto@ims.u-tokyo.ac.jp OR Hiromitsu Nakauchi: nakauchi@ims.u-tokyo.ac.jp
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 364 365 356 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 385 386 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 425 426 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
###xml 610 613 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
Embryonic stem cells (ESCs) could potentially compensate for the lack of blood platelets available for use in transfusions. Here, we describe a new method for generating mouse ESC-derived platelets (ESPs) that can contribute to hemostasis in vivo. Flow cytometric sorting of cells from embryoid bodies on day 6 demonstrated that c-Kit+ integrin alphaIIb (alphaIIb)+ cells, but not CD31+ cells or vascular endothelial cadherin+ cells, are capable of megakaryopoiesis and the release of platelet-like structures by day 12. alphaIIbbeta3-expressing ESPs exhibited ectodomain shedding of glycoprotein (GP)Ibalpha, GPV, and GPVI, but not alphaIIbbeta3 or GPIbbeta. ESPs showed impaired alphaIIbbeta3 activation and integrin-mediated actin reorganization, critical events for normal platelet function. However, the administration of metalloproteinase inhibitors GM6001 or TAPI-1 during differentiation increased the expression of GPIbalpha, improving both thrombogenesis in vitro and posttransfusion recovery in vivo. Thus, the regulation of metalloproteinases in culture could be useful for obtaining high-quality, efficacious ESPs as an alternative platelet source for transfusions.
###end p 3
###begin p 4
Abbreviations used: ADAM, a disintegrin and metalloproteinase; EB, embryoid body; ESC, embryonic stem cell; ESP, ESC-derived platelet; Flk, fetal liver kinase; GC, glycocalicin; GP, glycoprotein; HSC, hematopoietic stem cell; MMP, matrix metalloproteinase; PC, platelet concentrate; TEM, transmission electron microscopy; TIMP, tissue inhibitors of metalloproteinase; TPO, thrombopoietin; VE, vascular endothelial; VWF, von Willebrand factor.
###end p 4
###begin p 5
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 634 635 634 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 699 700 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 780 781 780 781 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 360 365 <span type="species:ncbi:9606">human</span>
###xml 598 603 <span type="species:ncbi:9606">human</span>
Platelet concentrates (PCs) from donated blood are required to treat severe thrombocytopenia in patients with various hematological diseases, such as those who have undergone cancer chemotherapy or are recovering from hematopoietic stem cell (HSC) transplantation (1, 2). Frequent transfusion of PCs is clinically necessary because the half-life of transfused human platelets is 4-5 d (3). Platelets cannot be stored frozen, thus the ability to generate platelets in vitro would provide significant advances for platelet replacement therapy in clinical settings. A novel culture method to generate human platelets from cord blood CD34+ cells was recently developed as an alternative source for PCs (4). However, technical difficulties in expanding ex vivo-cultured cord blood CD34+ cells on a large scale have limited this as a reasonable in vitro approach for generating platelets.
###end p 5
###begin p 6
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 554 555 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human embryonic stem cells (ESCs) can be forced to differentiate along a megakaryocytic lineage and represent a promising in vitro source for platelets. Owing to their pluripotency, ESCs can potentially proliferate indefinitely in culture (5). Platelets, as anucleate fragments of cytoplasm, can be irradiated before transfusion to effectively eliminate any contaminating cell, such as an undifferentiated ESC. The possibility of irradiation is important, as ESCs can potentially form teratomas or, if present at high numbers, elicit an immune response (6, 7). Thus, although ESCs represent a potentially safe and unlimited source of platelets in vitro, there are technical obstacles that remain.
###end p 6
###begin p 7
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 869 870 869 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 872 873 872 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 399 404 <span type="species:ncbi:10090">mouse</span>
First, culture methods for efficient in vitro generation of platelets have not been established. Second, appropriate in vivo function of the in vitro-produced platelet must be achieved. In addition, contamination with nonhuman antigens resulting in immunological reactions must be prevented. We and other groups have developed a method to generate large numbers of megakaryocytes and platelets from mouse ESCs grown on OP9 stromal cells in vitro (8, 9). However, these methods have not consistently produced ESC-derived megakaryocytes or platelets in sufficient quantity or quality to be considered as an alternative platelet source. No pre-selection for megakaryocyte progenitors was included in these previous reports. Studies have shown that the in vitro generation of large numbers of mature megakaryocytes depends on increased numbers of ESC-obtained progenitors (7, 8). Therefore, the identification and selection of megakaryocyte progenitors might increase the efficiency of megakaryopoiesis.
###end p 7
###begin p 8
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 310 312 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 436 438 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 590 592 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 721 723 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 872 874 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 963 965 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 967 969 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1063 1065 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1214 1216 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1218 1220 1174 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1373 1375 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 1421 1423 1373 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 1425 1427 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 958 961 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
###xml 1082 1087 <span type="species:ncbi:9606">human</span>
###xml 1092 1097 <span type="species:ncbi:10090">mouse</span>
###xml 1113 1116 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
The functional platelet paradigm in hemostasis and thrombosis is the initiation of platelet adhesion to the extracellular matrix (10). One key event in this process is the interaction between glycoprotein (GP)Ibalpha (the platelet receptor) and von Willebrand factor (VWF) present in the extracellular matrix (10). Simultaneously, platelets can interact with surface-bound collagen via platelet receptors GPVI and integrin alpha2beta1 (11). The net result is an activation of integrin alphaIIbbeta3 to become a competent fibrinogen receptor leading to the formation of platelet aggregates (10). A recent report has also suggested that GPIbalpha contributes to arterial thrombosis in vivo independently of binding to VWF (12). Indeed, other studies have demonstrated that GPIbalpha associates with thrombin, kininogen, coagulation factors XI and XII, and thrombospondin-1 (13). In addition, the GPIb-V-IX complex, consisting of GPIbalpha, GPIbbeta, GPIX, and GPV (10, 14), can bind integrin alphaMbeta2 on macrophages/monocytes or P-selectin on endothelial cells (13). Of note, aged human and mouse platelets shed GPV and an extracellular domain of GPIbalpha, which contains the binding sites for VWF and thrombin (13, 15). This process involves the action of a disintegrin and metalloproteinase (ADAM)17 (also referred to as tumor necrosis factor alpha converting enzyme) (16). This leads to decreased platelet function (16, 17).
###end p 8
###begin p 9
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 70 71 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 465 467 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 469 471 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 646 648 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 650 652 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 308 311 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
In this study, we demonstrate that c-Kit+ integrin alphaIIb (alphaIIb)+ cells isolated from ESCs differentiate with high efficiency into megakaryocytes and ESC-derived platelets (ESPs) in the presence of thrombopoietin (TPO) and stromal cells. We also show that ESPs shed extracellular domains of GPIbalpha, GPV, and GPVI in culture, reducing alphaIIbbeta3 activation and actin polymerization. Consequently, these ESPs are functionally impaired in thrombus growth (18, 19). However, the inhibition of metalloproteinases restores platelet function, making ESPs from induced pluripotent stem cells a source of platelets with therapeutic potential (20, 21).
###end p 9
###begin title 10
RESULTS
###end title 10
###begin title 11
Markers defining megakaryocyte differentiation from ESCs
###end title 11
###begin p 12
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 199 200 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 210 211 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 220 222 208 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 227 228 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 233 234 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 237 238 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 270 272 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 387 389 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 391 393 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 469 471 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 495 496 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 506 507 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 517 518 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 764 766 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 373 378 <span type="species:ncbi:10090">mouse</span>
The cell markers defining the megakaryocytic lineage in a culture system of ESCs or HSCs are not understood. It is known that megakaryocyte progenitors are highly enriched in the CD9+alphaIIb subunit+ (alphaIIb+)FcgammaRloc-Kit+Sca-1-Lin- fraction of bone marrow cells (22). The alphaIIb integrin subunit is an early primitive and definitive marker of hematopoiesis in the mouse embryo (17, 18) and a lineage-specific marker for postnatal megakaryocytes and platelets (23). We reasoned that CD31+, alphaIIb+, or c-Kit+ cells were candidates for megakaryocyte progenitors derived from ESCs because postnatal HSCs, mature megakaryocytes, and platelets all express CD31 and alphaIIbbeta3, and postnatal megakaryocyte progenitors express both c-Kit and alphaIIbbeta3 (22).
###end p 12
###begin p 13
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 261 269 261 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 608 616 604 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 619 621 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 695 703 691 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 795 797 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
To determine which cells actually contribute to megakaryopoiesis, we chose to induce a liquid culture system of ESCs for embryoid body (EB) formation (24). Sorted cells were then applied onto OP9 stromal cells to differentiate along the megakaryocytic lineage (Fig. 1 A). This two-stage approach was used because EB formation has been reported to be more suitable than co-culture with OP9 cells in producing hematopoietic progenitors in vitro (25). Indeed, liquid culture for EB formation resulted in reproducibly higher expression of the alphaIIb integrin subunit than the use of the OP9 co-culture system (Fig. 1 B) (26). ESCs co-cultured with OP9 stromal cells preferentially expressed CD31 (Fig. 1 B, right) or vascular endothelial (VE)-cadherin (unpublished data) by days 4-5, as reported (27).
###end p 13
###begin p 14
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 14 15 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 83 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c-Kit<sup>+</sup>&#945;IIb<sup>+</sup> cell selection from day 6 EB determines the megakaryocytic lineage.</bold>
###xml 988 989 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 997 998 962 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1028 1029 993 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1075 1076 1040 1041 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1101 1102 1066 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1110 1111 1071 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1138 1139 1099 1100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1144 1145 1105 1106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1346 1347 1307 1308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1582 1583 1540 1541 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1592 1593 1546 1547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1604 1605 1558 1559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1614 1615 1564 1565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1627 1628 1577 1578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1637 1638 1583 1584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1649 1650 1595 1596 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1659 1660 1601 1602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1761 1762 1702 1703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1771 1772 1708 1709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1848 1849 1784 1785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1858 1859 1790 1791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2198 2199 2130 2131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2207 2208 2135 2136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 500 505 <span type="species:ncbi:9606">human</span>
###xml 697 702 <span type="species:ncbi:9606">human</span>
###xml 764 769 <span type="species:ncbi:9606">human</span>
c-Kit+alphaIIb+ cell selection from day 6 EB determines the megakaryocytic lineage. (A) Protocol used in this study. (B) EB formation or OP9 co-culture was used for ESC differentiation from day 0 through day 6 in vitro. On the indicated days of culture, expression of Flk-1, integrin alphaIIb subunit (CD41), or CD31 was examined in both groups of cultured cells. The graph shows mean +/- SEM from three independent experiments. (C) GPIbalpha and GFP expression in GPIbalpha-ESCs is regulated by the human GPIbalpha promoter. GFP is detectable in cultured cells that exhibit megakaryopoiesis (day 9) but not in progenitors (day 6). In the bottom box, cells with surface-expressed GFP also express human GPIbalpha. The cells on day 9 were fixed and stained to mark human GPIbalpha to confirm the colocalization with GFP expression at the membrane of the cells. Bars, 10 mum. (D) Representative dot plots for the expression of individual antigens on 10,000 living cells from day 6 EB. c-Kit+alphaIIb+ cells corresponded with Flk-1+ cells (not depicted) but not with VE-cadherin+ cells. And >96% of c-Kit+alphaIIb+ cells are found in the CD9+Sca-1- fraction. (E) EB cells were sorted as shown in D, and 20,000 cells per well of a 6-well plate were seeded onto OP9 stroma cells in the presence of TPO. The left graph shows the number of generated GFP+ cells (mean +/- SEM) per well of a 6-well plate on day 12 of culture. Representative images from day 12 culture dishes (phase or fluorescence microscopy [insets: bar, 50 mum] of four different fraction-derived cells at day 6; i, c-Kit+/alphaIIb+; ii, c-Kit-/alphaIIb+; iii, c-Kit+/alphaIIb-; iv, c-Kit-/alphaIIb- [phase: bar, 50 mum]) and of Wright-Giemsa-stained cytospin preparation on day 12 derived from c-Kit+/alphaIIb+ fraction of day 6 were also shown. Bar, 50 mum. Results indicate that c-Kit+/alphaIIb+ fraction of day 6 (i) selectively yields megakaryocytes on day 12. Similar results have been obtained from three independent experiments. (F) Expression of genes related to the megakaryocytic lineage as determined by RT-PCR of cells from day 0, 6, or 8 cultures as indicated. (G) Wright-Giemsa-stained cytospin preparation of sorted c-Kit+alphaIIb+ cells from EB at day 6 is shown. Bar, 10 mum.
###end p 14
###begin p 15
###xml 208 216 200 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 230 232 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 233 235 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 333 335 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 336 338 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 411 419 403 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 481 482 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 491 492 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 564 565 548 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 767 775 751 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 797 798 781 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 837 838 821 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 844 845 828 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 853 854 833 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 882 883 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 892 893 868 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 948 949 924 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 957 958 929 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1110 1118 1082 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 1147 1148 1119 1120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1152 1153 1124 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1168 1169 1140 1141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1174 1175 1146 1147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1251 1266 1223 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, D and E</xref>
###xml 1292 1293 1264 1265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1298 1299 1270 1271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1303 1304 1275 1276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1390 1392 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 778 784 <span type="species:ncbi:10090">Murine</span>
To trace newly developed megakaryocytes and platelets in culture, we generated a novel ESC line in which the platelet-specific GPIbalpha promoter supports expression of a human GPIbalpha-EGFP fusion protein (Fig. 1 C, GPIb-ESCs) (28-30). Earlier reports showed selective expression in megakaryocytes and platelets using this system (29-31). The GFP-tagged cells were detectable by day 9 in the presence of TPO (Fig. 1 C). In addition, GFP expression was detectable only in alphaIIb+GPIbalpha+ megakaryocytes derived from cultures treated with TPO but not in Ter119+ erythroblasts isolated from erythropoietin-containing cultures (not depicted). We further separated EB cells on day 6 to identify which fraction could differentiate into GFP-expressing megakaryocytes (Fig. 1 D). Murine ESCs (2 x 105 per 100-mm dish) typically produced 106 c-Kit+alphaIIb+ cells by day 6 and 2.5 x 106 alphaIIb+ megakaryocytes by day 12. Cells derived from the c-Kit+alphaIIb+ fraction at day 6 expressed GFP on day 12 at 10-fold higher levels compared with cells in other fractions or in unfractionated whole EB-derived cells (Fig. 1 E). Fetal liver kinase (Flk)-1+CD31+ or VE-cadherin+c-Kit+ cells from day 6 EB did not contribute to megakaryopoiesis in this system (Fig. 1, D and E). ESC-derived VE-cadherin+c-Kit+CD45- cells in OP9 co-culture had been reported to contribute to definitive hematopoiesis (32).
###end p 15
###begin p 16
###xml 88 90 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 202 204 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 206 208 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 240 241 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 249 250 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 334 342 326 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 F</xref>
###xml 345 347 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 372 373 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 381 382 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 408 409 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 414 415 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 472 480 460 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 483 485 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 603 611 591 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 G</xref>
###xml 614 616 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 661 662 649 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 670 671 654 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 45 48 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
Serial RT-PCR studies to detect GPIbalpha or GPV, both megakaryocytic-specific markers (33), along with the essential transcription factors for megakaryopoiesis, GATA-1, GATA-2, FOG-1, Fli-1, or NF-E2 (34, 35), indicated that day 6 EB c-Kit+alphaIIb+ cells were positive for these markers in the presence of TPO on OP9 stromal cells (Fig. 1 F) (34). Indeed, day 6 EB c-Kit+alphaIIb+ cells corresponded to CD9+Sca-1- cells in bone marrow-derived megakaryocyte progenitors (Fig. 1 D) (22), and their morphological features resembled immature hematopoietic progenitor cells derived from adult bone marrow (Fig. 1 G) (22). We concluded from these results that c-Kit+alphaIIb+ cells derived from ESCs can differentiate displaying several markers unique to the megakaryocytic lineage.
###end p 16
###begin title 17
GPIbalpha expression on ESPs is reduced during in vitro culture
###end title 17
###begin p 18
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 85 86 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 94 102 90 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 251 252 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 370 378 366 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 434 442 430 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 591 599 587 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 662 670 658 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 760 762 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 873 881 865 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 517 523 <span type="species:ncbi:10090">murine</span>
###xml 922 927 <span type="species:ncbi:10090">mouse</span>
EB generation from ESC in liquid culture (6 d) followed by sorting for c-Kit+alphaIIb+ cells (Fig. 1 A) resulted in the constant generation of megakaryocytes and platelet-like particles, an improvement over our previously reported culture conditions (9). After 8-14 d in culture (2-8 d on co-culture with OP9 stromal cells), culture supernatants contained proplatelets (Fig. 2 A, i) and platelet-sized particles consistent with ESPs (Fig. 2 B). The granularity and size of these ESPs varied from those of circulating murine platelets as determined by transmission electron microscopy (TEM) (Fig. 2 A) and the forward scatter profiles produced by flow cytometry (Fig. 2 B). Thus, the culture conditions seem to yield various developmental stages of a platelet (36). ESPs displayed an extensive surface-connected open canalicular system and multiple alpha or dense granules (Fig. 2 A, ii and iii). As compared with a normal mouse platelet, ESPs had a reduced number of granules per ESP (unpublished data).
###end p 18
###begin p 19
###xml 0 72 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GPIb&#945; expression is reduced on cultured ESPs but not megakaryocytes.</bold>
###xml 995 996 963 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1088 1089 1052 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1137 1138 1097 1098 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1163 1164 1119 1120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 482 487 <span type="species:ncbi:10090">Mouse</span>
###xml 675 680 <span type="species:ncbi:10090">mouse</span>
###xml 792 795 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
###xml 815 820 <span type="species:ncbi:10090">mouse</span>
GPIbalpha expression is reduced on cultured ESPs but not megakaryocytes. (A) On day 12 of the culture, ESC-derived megakaryocytes bearing proplatelets are represented in panel (i) (phase contrast image in culture dish). Bar, 100 mum. Panels (ii) and (iii) show TEM images of ESPs. The subcellular structure of ESPs showed an open canalicular system, dense granules (arrowhead), and alpha granules (arrow), which were similar to those of peripheral blood platelets. Bars, 1 mum. (B) Mouse platelets (12 wk old) or ESPs (day 12) were subjected to flow cytometry. Graphs show representative forward scatter (FSC) or side scatter (SSC) dot plots. ESPs vary in size compared with mouse platelets. The remaining six graphs show surface expression of alphaIIb integrin subunit, GPIbalpha, GPIbbeta, GPV, GPVI, and GPIX on mouse platelets (red lines) or ESPs (blue lines) with control IgG (black lines). (C) (i) On the indicated days of culture (x axis), expression of GPIbalpha and GPIbbeta in alphaIIb+ megakaryocytes derived from ESCs and ESPs is shown. Panel (ii) shows the number of alphaIIb+ ESPs on days 8 and 12 that are either GPIbalpha+ (black bar) or GPIbalpha- (white bar). All results are mean +/- SEM from four independent experiments.
###end p 19
###begin p 20
###xml 224 232 217 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 350 358 339 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 383 384 368 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 393 394 374 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 402 403 380 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 547 556 521 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Figs. 2 C</xref>
###xml 640 641 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 803 811 765 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 103 109 <span type="species:ncbi:10090">murine</span>
###xml 270 273 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
###xml 333 338 <span type="species:ncbi:10090">mouse</span>
We examined the relative expression of receptors by flow cytometry comparing ESPs and freshly isolated murine platelets. Expression of the integrin alphaIIb, GPIbbeta, and GPIX was similar in platelets from the two sources (Fig. 2 B). However, expression of GP Ibalpha, GPV, and GPVI was significantly less for ESPs as compared with mouse platelets (Fig. 2 B). Cells with an alphaIIb+GPIbalpha-GPIbbeta+ phenotype composed 35-65% of the cellular population after 12-14 d in culture. Reduced GPIbalpha expression of ESPs was not detected at day 8 (Figs. 2 C, i and ii), consistent with a longer time in culture leading to a loss of GPIbalpha+ cells or shedding of GPIbalpha from the cell. Unlike ESPs, ESC-derived megakaryocytes did not exhibit reduced GPIbalpha expression, even when cultured for >8 d (Fig. 2 C, i).
###end p 20
###begin p 21
###xml 149 151 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 153 155 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 537 539 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 653 654 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 787 795 779 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 870 885 857 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A and B</xref>
###xml 957 958 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 973 974 952 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 983 984 958 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 998 999 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1008 1009 975 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1023 1031 990 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 1141 1150 1104 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Figs. 2 C</xref>
###xml 1254 1255 1213 1214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1262 1270 1221 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1310 1312 1269 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1314 1316 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 1618 1626 1569 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 1690 1705 1641 1656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A and E</xref>
###xml 2024 2032 1967 1975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 2132 2140 2075 2083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
###xml 1230 1233 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
###xml 1403 1406 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
ADAM17 can cleave the extracellular domain of GPIbalpha on human and mouse platelets abrogating platelet function by its metalloproteinase activity (16, 17). Thus, we investigated whether a metalloproteinase supported the shedding of GPIbalpha in culture. Two potent metalloproteinase inhibitors, GM6001 (Ilomastat) or TAPI-1, were added to the co-culture system to evaluate the potential involvement of a matrix metalloproteinase (MMP). Because both inhibitors also inhibit MMP9, which has been reported to facilitate megakaryopoiesis (37), the drugs were administered only after day 10 (day 4 of co-culture) when megakaryocyte polyploidy is observed (9). Indeed, we found that the addition of GM6001 at the co-culture start impaired megakaryopoiesis (not depicted). GM6001 and TAPI-1 (Fig. 3 B, 1 and 10 muM) increased GPIbalpha expression on released ESPs at day 12 (Fig. 3, A and B). This increased expression did not affect the total number of alphaIIb+ ESPs (alphaIIb+GPIbalpha+ plus alphaIIb+GPIbalpha-) at days 12 (Fig. 3 C) or 14 (not depicted). But the reduction of GPIbalpha was not observed on megakaryocytes during the culture (Figs. 2 C, i, and 3 A). Similarly, GM6001 addition to the culture restored expression of GPV and GPVI in alphaIIb+ ESPs (Fig. 3 D) as reported for aged blood platelets (15, 38). These results suggest that metalloproteinase(s) impairs the retention of GPIbalpha, GPV, and GPVI on ESPs. Biochemical analysis confirmed that ESPs in culture shed the extracellular domain of GPIbalpha, referred to as "glycocalicin" (GC), in the absence of GM6001 but not in the presence of GM6001 (Fig. 3 E). As ESC-derived megakaryocytes do not show receptor shedding (Fig. 3, A and E, i), we removed them from the day 12 cell culture population. The remaining specimens were centrifuged, and pellets along with the corresponding supernatant were analyzed. Western blot analysis revealed GPIbalpha and GC antigen in the absence of GM6001, but a single band of GPIbalpha alone in the presence of GM6001 (Fig. 3 E, ii). A single band of GC was detectable only in the absence of GM6001 in ESP-derived supernatant (Fig. 3 E, iii).
###end p 21
###begin p 22
###xml 0 82 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of metalloproteinases in culture restores GPIb&#945; expression in ESPs.</bold>
###xml 462 463 453 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 479 480 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 681 682 660 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 692 693 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 702 703 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 717 718 684 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 727 728 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 963 964 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1743 1744 1682 1683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 940 943 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
###xml 1520 1525 <span type="species:ncbi:10090">mouse</span>
Inhibition of metalloproteinases in culture restores GPIbalpha expression in ESPs. (A) On day 10 of ESC culture, 1% DMSO alone (vehicle) or 100 muM GM6001 dissolved with 1% DMSO was added to the culture medium. On day 12 of culture, representative flow cytometry dot plots of mature megakaryocytes derived from ESCs (ESC-MKs) in the absence of GM6001 (left) and ESPs in the absence or presence of GM6001 are shown. (B) The graph shows the percentage of GPIbalpha+ of all alphaIIb+ ESPs on day 12 in the absence or presence of 1-10 muM TAPI-1 or 100 muM GM6001. Results are shown as mean +/- SEM from three independent experiments. (C) The graph summarizes total numbers of alphaIIb+ (alphaIIb+GPIbalpha+ plus alphaIIb+GPIbalpha-) ESPs per well of a 6-well plate on day 12. Results are the mean +/- SEM from four independent experiments. (D) The graph shows the effects of the metalloproteinase inhibitor GM6001 on the surface expression of GPV or GPVI in alphaIIb+ ESPs on day12. Results are mean +/- SEM from four independent experiments. (E) Expression of GPIbalpha or GC in lysates from ESC-MKs (i), in lysates from pellets containing ESPs depleted of MKs (ii), or in supernatant (iii). In panel (i) or (ii), lysates were analyzed by Western blot (7.5% SDS-PAGE) with an anti-GPIbalpha antibody. In panel (iii), supernatant derived from culture media of ESPs pretreated with or without GM6001 were subjected to immunoprecipitation followed by immunoblotting with anti-GPIbalpha. In vitro-aged platelets from an adult mouse were used as a positive control in panel (iii). Similar results were obtained from three independent experiments. (F) The graphs show the percentage of positive cells of annexin V or P-selectin from the total alphaIIb+ ESPs on day 12 in the absence or presence of GM6001. Results are the mean +/- SEM from three independent experiments.
###end p 22
###begin p 23
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 536 544 536 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 F</xref>
###xml 756 762 <span type="species:ncbi:10090">murine</span>
To study whether pre-activation by plasma membrane injury or the activation state of ESPs is associated with metalloproteinase activity during culture, we examined the annexin V binding and P-selectin expression in the absence or presence of GM6001. Annexin V is a marker of platelet activation that detects the translocation of phosphatidylserine to the outer membrane, while P-selectin expression is a hallmark marker of activation (13, 39). Annexin V binding, but not P-selection expression, was inhibited in the presence of GM6001 (Fig. 3 F). These data indicate that metalloproteinase-dependent cellular changes occurring during ESP generation leads to a reduced viability of these cells. Comparable results were obtained using a variety of different murine ESC lines (R1, EB3, TT2, or E14.1; unpublished data).
###end p 23
###begin title 24
Inhibition of metalloproteinase activity restores integrin alphaIIbbeta3 bidirectional signaling in ESPs
###end title 24
###begin p 25
###xml 215 216 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 318 326 307 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 429 430 418 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 446 448 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 555 563 544 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 855 863 837 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 990 995 <span type="species:ncbi:9606">human</span>
###xml 1311 1316 <span type="species:ncbi:9606">human</span>
###xml 1630 1635 <span type="species:ncbi:9606">human</span>
To explore whether metalloproteinases induce extracellular shedding of GPIbalpha and affect alphaIIbbeta3 inside-out signaling, we used flow cytometry to assess specific fibrinogen binding upon agonist stimulation (9). GM6001 restored specific fibrinogen binding when washed ESPs were stimulated with thrombin or ADP (Fig. 4 A). To rule out the possibility that metalloproteinases directly impair integrin structure in ESPs, MnCl2 was also used (40). Binding of Alexa 488-conjugated fibrinogen to ESPs was comparable in the presence or absence of GM6001 (Fig. 4 A) and similar to that in blood platelets (not depicted). Moreover, alphaIIbbeta3-based actin cytoskeletal changes (outside-in signaling) of ESPs in culture were unexpectedly enhanced in the presence of GM6001, apparent when lamellipodia formation was facilitated by the addition of thrombin (Fig. 4 B, arrow). To address whether our observation of defects in ESPs also applied to blood platelets, we generated in vitro-injured human platelets by incubation at 37degreesC for 24 h. Reduced GPIbalpha expression was determined by flow cytometry and Western blot analysis (unpublished data), and a defect in lamellipodia formation in these aged platelets was observed. Impaired lamellipodia formation, apparent even upon thrombin stimulation, in aged human platelets was partially restored by the administration of GM6001 in culture for 24 h (Fig. S1, available at ). These data demonstrate that deregulated alphaIIbbeta3-mediated bidirectional signaling (both inside-out and outside-in) may be associated with an increase in metalloproteinase activity in both ESPs and human platelets.
###end p 25
###begin p 26
###xml 0 115 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of metalloproteinases is required for platelet function mediated through integrin &#945;IIb&#946;3 in ESPs.</bold>
###xml 185 186 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 438 439 416 417 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 451 453 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
Inhibition of metalloproteinases is required for platelet function mediated through integrin alphaIIbbeta3 in ESPs. (A) (i) Representative flow cytometry dot plots showing three mM MnCl2-stimulated or 0.1 U/ml thrombin-stimulated fibrinogen binding to integrin alphaIIbbeta3 in ESPs after pretreatment with 1% DMSO as a vehicle or 100 muM GM6001. (ii) The graphs show specific fibrinogen binding to alphaIIbbeta3 stimulated with 3 mM MnCl2 (reference 40), 0.1 U/ml thrombin, or 500 muM adenosine diphosphate. The value of control (vehicle) is defined as 100%. Results are the mean +/- SEM from three independent experiments. (B) On day 14 of culture, washed ESPs pretreated with 1% DMSO or 100 muM GM6001 were plated on fibrinogen-coated coverslips for 45 min. An aliquot of each preparation was assayed in the presence of 1 U/ml thrombin. Cells were fixed, permeabilized, and stained with Alexa 488-phalloidin to stain F-actin (green) and with an anti-alphaIIb antibody followed by Alexa 567 (red). Bar, 10 mum. The value of control (vehicle) is defined as 100%. The right graph summarizes three independent experiments (mean +/- SEM).
###end p 26
###begin title 27
Metalloproteinases may regulate thrombus formation under flow conditions and posttransfusion recovery in vivo by ESPs
###end title 27
###begin p 28
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 499 501 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 503 505 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 507 509 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 511 513 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 604 606 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 916 924 901 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 927 929 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1052 1067 1037 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, B and C</xref>
###xml 1300 1308 1285 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 661 666 <span type="species:ncbi:10090">mouse</span>
###xml 839 844 <span type="species:ncbi:10090">mouse</span>
###xml 1294 1298 <span type="species:ncbi:10090">mice</span>
Thrombus formation is a dynamic process, and we sought to examine platelet function under physiologically relevant conditions found in the arterial circulation. An experimental system frequently used to study platelet thrombus formation is perfusion of whole blood over a monolayer of collagen at high shear rates, features mimicking those that occur in vivo (41). In this model, the initial event is tethering of platelets via binding of GPIbalpha to VWF, the latter being immobilized by collagen (10, 11, 13, 14). Direct interaction between integrin alpha2beta1/GPVI on platelets and collagen follows (10). We prepared reconstituted whole blood consisting of mouse blood labeled with mepacrine, as a marker for platelets (green fluorescence), mixed (1,000:1) with Ds-red-labeled ESC-derived ESPs (red fluorescence). As a control, washed mouse platelets labeled with PE-conjugated anti-alphaIIb antibody were used (Fig. 5 A) (42). ESPs pretreated with 1% DMSO failed to adhere to collagen-VWF matrices, but pretreatment with GM6001 improved adhesion (Fig. 5, B and C). Most importantly, treating ESPs with GM6001-treated ESPs increased their ability to participate in thrombogenesis. However, their thrombus-forming potential was less than that of uninjured fresh platelets derived from adult mice (Fig. 5 C).
###end p 28
###begin p 29
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ESPs treated with GM6001 but not without GM6001 contribute to thrombus formation under flow conditions.</bold>
###xml 294 296 294 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
###xml 465 470 <span type="species:ncbi:10090">mouse</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
###xml 542 548 <span type="species:ncbi:10090">murine</span>
ESPs treated with GM6001 but not without GM6001 contribute to thrombus formation under flow conditions. (A) Schema of the experimental design. (B) Representative two-dimensional fluorescence images at 6 min. Glass slides coated with type I collagen were perfused at a wall shear rate of 1,500 s-1 for 6 min. Samples included reconstituted whole blood composed of ESPs (red, arrowheads) in blood obtained from 10-12 mice (per experiment), or a mixture of PE-labeled mouse platelets (red, arrowheads) in whole blood pooled from 10-12 mice. All murine platelets or ESPs were stained with mepacrine (green). ESPs capture fluorescent mepacrine as indicated by their dual expression of green and red by flow cytometer. Bars, 100 mum. (C) After 6 min, platelet thrombi formed on the collagen surface were quantified using NIH Images software from a recorded video. The results summarize four independent experiments (mean +/- SEM).
###end p 29
###begin p 30
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 377 385 377 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 560 561 548 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 608 616 595 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 768 769 751 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1030 1032 1013 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 1105 1106 1088 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1154 1162 1137 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 265 271 <span type="species:ncbi:10090">murine</span>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
Aged or injured platelets are cleared out of the body after being trapped in the liver (unpublished data) and spleen (43). To confirm the effect of GM6001 on in vivo function of ESPs, we examined the time course kinetics of residual ESPs after transfusion. Because murine platelets do not express Ly5 antigen, we chose GFP-expressing ESCs for in vivo assays after transfusion (Fig. 6 A). More than 80% of ESPs on day 12 expressed GFP in culture. GM6001-treated ESPs were transfused into the tail veins of mice with significant thrombocytopenia (approximately104/mul) as a result of irradiation 10 d earlier (Fig. 6 A). 2, 24, 48, or 72 h after transfusion, whole blood was obtained from recipient mice, and the percentage of GFP-expressing platelets among all alphaIIb+ platelets was determined. No difference in the size of endogenous platelets and ESPs transfused into recipient mice was observed (not depicted), suggesting that the in vivo circulation that may induce shear stress is an important determinant of platelet size (44). Preincubation with GM6001 consistently increased the percentage of GFP+ ESPs after transfusion compared with controls (Fig. 6 B).
###end p 30
###begin p 31
###xml 0 87 0 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The effect of metalloproteinase inhibition on posttransfusion recovery by ESPs in mice.</bold>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 422 423 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 567 568 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 192 197 <span type="species:ncbi:10090">mouse</span>
The effect of metalloproteinase inhibition on posttransfusion recovery by ESPs in mice. (A) Schema of the experimental design. (B) 2 h after transfusion of 3 x 106 ESPs, using a 129Ola strain mouse model in which platelet numbers are severely reduced, blood obtained from the retroorbital venous plexus was treated with 3.8% sodium citrate and subjected to flow cytometry to detect GFP+ platelets (ESPs) among all alphaIIb+ platelets. Additional serial evaluations were performed 24, 48, and 72 h after transfusion. Pretreatment with GM6001 increased the ratio of GFP+ ESPs per a recipient at all points examined. Results are the mean +/- SEM from three independent experiments.
###end p 31
###begin title 32
DISCUSSION
###end title 32
###begin p 33
###xml 772 774 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 868 870 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 990 992 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 41 44 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
This study has shown that (a) GPIbalpha, GPV, and GPVI, but not integrin alphaIIbbeta3 or GPIbbeta, are shed from ESPs during culture; (b) the process is specific for ESPs and not relevant for megakaryocyte differentiation from ESCs; (c) the use of a metalloproteinase inhibitor retains the complete GPIb-V-IX complex on ESPs; and (d) both inside-out and outside-in signaling of alphaIIbbeta3 might be associated with metalloproteinase activity. A link between metalloproteinase regulation and alphaIIbbeta3-mediated signaling has not been reported previously. Preventing shedding of the alpha-subunit of the GPIb-V-IX complex retains key binding sites for VWF, thrombin, coagulation factors, P-selectin, and Mac-1, all potentially important for normal platelet function (13). The N-terminal motif of GPIbalpha is essential for arterial thrombosis independent of VWF (12), and the signaling cascade from the GPIb-V-IX complex to alphaIIbbeta3 is well known to regulate integrin activation (45). However, the mechanisms whereby metalloproteinase activity regulates integrin signaling remain to be identified.
###end p 33
###begin p 34
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 291 293 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 362 364 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 704 706 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
Metalloproteinases are functionally regulated by endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs) (46). When we considered the reason why megakaryocytes maintained GPIbalpha in culture, as opposed to ESPs, we hypothesized that TIMP-3, also known to inhibit ADAM17 (47), might be highly expressed in megakaryocytes but not in platelets (48). We therefore determined TIMP-3 expression in ESC-derived megakaryocytes and ESPs, but found no significant difference by RT-PCR (unpublished data). Alternatively, receptor shedding may be occurring with megakaryocytes but is not detectable owing to their gene and protein expression potential, which differs from the anucleate platelet (49).
###end p 34
###begin p 35
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 150 151 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 573 575 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 767 769 763 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 819 821 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 823 825 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 827 829 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 881 883 877 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 978 980 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 982 984 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 986 988 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 1517 1520 1509 1512 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1513 1520 1505 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP9<sup>&#8722;/&#8722;</sup></italic>
###xml 1556 1559 1548 1551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1552 1559 1544 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP9<sup>+/+</sup></italic>
###xml 1210 1214 <span type="species:ncbi:10090">mice</span>
###xml 1369 1373 <span type="species:ncbi:10090">mice</span>
###xml 1521 1525 <span type="species:ncbi:10090">mice</span>
###xml 1560 1564 <span type="species:ncbi:10090">mice</span>
Another interesting observation was that an administration of GM6001 or TAPI-1 from the beginning of culture impaired the production of c-Kit+alphaIIb+ cells by day 6 of the liquid culture (unpublished data). We observed that the use of inhibitors to metalloproteinases, which cover both MMPs and ADAMs, is advantageous for the production of efficacious platelets only after day 10 of co-culture. Nonspecific inhibition to metalloproteinases may affect the early phase of hematopoiesis from ESCs as demonstrated in postnatal hematopoiesis through MMP9-mediated mechanisms (50). In addition, it has been reported that MMP2 or MMP9 may have an effect on platelet function. MMP2 activates platelet aggregation through an increase in phospholipase C, protein kinase C, Ca2+ mobilization, and phosphatydylinositol 3 kinase (46, 51, 52). MMP9 blocks phospholipase C, protein kinase C, Ca2+ mobilization, and thromboxane A2 production leading to the inhibition of the effects of MMP2 (46, 52, 53). Integrins share some of these pathways and therefore might explain how both metalloproteinases and integrin activation might influence each other. In a search for specific MMPs regulating platelet function, we analyzed mice deficient in MMP9 and found comparable platelet numbers, integrin activation, and platelet spreading on fibrinogen comparing wild-type and MMP9-deficient mice (Fig. S2, A, C, and D, available at ). In addition, extracellular shedding of GPIbalpha was observed using in vitro-injured platelets from MMP9-/- mice as well as platelets from MMP9+/+ mice (Fig. S2 B). These results indicate that MMP9 per se is not implicated in thrombopoiesis and platelet function.
###end p 35
###begin p 36
###xml 128 134 128 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 402 404 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 545 547 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 549 551 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 553 555 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 697 699 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">56</xref>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 436 439 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
###xml 476 481 <span type="species:ncbi:9606">human</span>
Our results suggest that the administration of metalloproteinase inhibitors prolongs the half-life of circulating ESPs in vivo (Fig. 6), presumably by maintaining the repertoire of membrane receptors, such as GPIb-V-IX and GPVI. In patients with thrombocytopenia, platelet destruction is proportional to plasma concentrations of GC, a shedding product that includes the N-terminal domain of GPIbalpha (54). The ectodomain of GPIbalpha, GPV, and GPVI is easily shed in stocked human PCs possibly due to increased activities of ADAM17 and ADAM10 (12, 13, 55). Consistent with our study, GM6001 has been recently shown to prevent inactivation of refrigerated platelets by inhibiting ADAM17 activity (56). Specific inhibition to ADAM17 (and ADAM10) with spatial-temporal regulation not affecting hematopoiesis in ESCs may increase generation and storage of efficacious ESPs.
###end p 36
###begin p 37
###xml 91 92 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 100 101 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 55 61 <span type="species:ncbi:10090">murine</span>
###xml 227 232 <span type="species:ncbi:9606">human</span>
In conclusion, the inhibition of metalloproteinases in murine cultures of ESC-derived c-Kit+alphaIIb+ primitive cells represents an improvement in the production of efficacious ESPs. Confirming these observations starting with human cells is a future direction potentially defining an experimental framework to produce ESPs in sufficient quantity for clinical application.
###end p 37
###begin title 38
MATERIALS AND METHODS
###end title 38
###begin title 39
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Plasmid preparation, reagents, and mice.
###end title 39
###begin p 40
###xml 364 367 364 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 360 367 360 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP9<sup>&#8722;/&#8722;</sup></italic>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 1520 1521 1505 1506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">R</sup>
###xml 1625 1627 1610 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">57</xref>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
###xml 567 573 <span type="species:ncbi:9913">bovine</span>
###xml 604 609 <span type="species:ncbi:10090">mouse</span>
###xml 656 661 <span type="species:ncbi:9606">human</span>
###xml 789 794 <span type="species:ncbi:10090">mouse</span>
###xml 977 982 <span type="species:ncbi:9606">human</span>
###xml 1190 1195 <span type="species:ncbi:10090">mouse</span>
###xml 1228 1233 <span type="species:ncbi:10090">mouse</span>
###xml 1244 1247 <span type="species:ncbi:38251?0.19642857142857142">GPV</span>
###xml 1402 1407 <span type="species:ncbi:9606">Human</span>
###xml 1486 1491 <span type="species:ncbi:10090">Mouse</span>
###xml 1548 1553 <span type="species:ncbi:9606">Human</span>
All reagents were purchased from Sigma-Aldrich unless otherwise indicated. All animal and recombinant DNA experiments were approved by the Institutional Animal Care and Use Committee of the Institute of Medical Science, University of Tokyo. C57BL/6 mice were purchased from SLC. 129Ola mice (transfusion recipients) were purchased from The Jackson Laboratory. MMP9-/- mice were provided by Z. Werb (University of California, San Francisco, San Francisco, CA) (45). Rhodamine- and Alexa 488-conjugated phalloidin, Alexa 488-conjugated fibrinogen, Alexa 568-conjugated bovine IgG, and Alexa 647-conjugated mouse IgG antibodies were from Invitrogen. Purified human fibrinogen was from American Diagnostica Inc. FITC- and allophycocyanin (APC)-conjugated, PE-conjugated, and unconjugated anti-mouse integrin alphaIIb subunit and APC-conjugated anti-c-Kit, PE-conjugated anti-CD31, PE-conjugated anti-Sca-1, biotin-conjugated anti-CD9, FITC-conjugated anti-P-selectin, unconjugated human anti-GPIbalpha, and streptoavidin-APC-cyanine 7 (APC-Cy7) antibodies were from BD Biosciences. An annexin V-FITC apoptosis detection kit was purchased from BD Biosciences. PE-conjugated or unconjugated anti-mouse GPIbalpha, FITC-conjugated anti-mouse GPIbbeta, GPV, GPVI, and GPIX antibodies were from Emfret. Biotin-conjugated anti-VE-cadherin antibody was provided by M. Ogawa (Kumamoto University, Kumamoto, Japan). Human TPO and erythropoietin were provided by H. Miyazaki (Kirin, Takasaki, Japan). Mouse leukemia inhibitory factor (RESGRO) was from Millipore. Human TPO, IL-6, and IL-11 were purchased from PeproTech. GM6001 and TAPI-1 (57) were from EMD.
###end p 40
###begin title 41
Growth and differentiation of ES cells.
###end title 41
###begin p 42
###xml 30 32 30 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">58</xref>
###xml 40 41 40 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 48 49 48 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 383 384 381 382 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 558 559 556 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 664 665 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 285 290 <span type="species:ncbi:9606">human</span>
The murine ESC lines E14tg2A (58), E14 (5), R1 (8), EB3 (37), and TT2 (7) were maintained as described previously (9). For EB formation, 2 x 105 ESCs were placed in 100-mm bacterial Petri dishes containing Iscove's modified Dulbecco's medium supplemented with a cocktail of 300 mug/ml human transferrin, 0.45 mM monothioglycerol, 50 mug/ml ascorbic acid, and penicillin-streptomycin/l-glutamine solution (Invitrogen). On day 5 or 6 of culture, cells were dissociated with 0.25% trypsin/EDTA and subjected to sorting by FACS MoFlo (Dako). Sorted cells (2 x 104 per well) were seeded onto OP9 stroma cells in 6-well plates with 20 ng/ml TPO as described previously (9). After 3 d of culture, a cocktail of 10 ng/ml TPO, 5 ng/ml IL-6, and 10 ng/ml IL-11 was added. Cell surface antigen expression was examined by flow cytometry (FACS Aria; BD Biosciences).
###end p 42
###begin title 43
Establishment of GPIb-ESC line.
###end title 43
###begin p 44
###xml 79 88 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GPIb&#945;</italic>
###xml 99 101 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 144 159 140 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GPIb&#945;&#8211;&#8211;EGFP</italic>
###xml 538 544 529 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">zeocin</italic>
###xml 555 569 546 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GPIb&#945;&#8211;EGFP</italic>
###xml 716 724 703 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
###xml 549 554 <span type="species:ncbi:9606">human</span>
An expression construct containing a human genomic DNA fragment containing the GPIbalpha promoter (28), followed by coding sequence for a human GPIbalpha--EGFP fusion, was inserted into pcDNA 3.1 (+)/zeo vector (Invitrogen). All sequences were subsequently confirmed by nucleotide sequencing. Completed pcDNA3.1 zeo vector was linearized with NheI site and transfected into E14tg2A ESCs by electroporation. After drug selection with 65 mug/ml zeocin for 7 d, resistant colonies were collected. Viable ESCs were confirmed by PCR to detect zeocin and human GPIbalpha-EGFP as a positive clone. To define useful ESC clones further, the intensity of GFP expression was assessed after differentiation into megakaryocytes (Fig. 1 C).
###end p 44
###begin title 45
Quantification by RT-PCR.
###end title 45
###begin p 46
###xml 44 45 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 50 51 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
Sorted cells from day 6 EB or day 8 alphaIIb+c-Kit- megakaryocytes cultured on OP9 were lysed with Trizol-LS (Invitrogen) for total RNA extraction. cDNAs were obtained by using Thermo Script RT-PCR System and oligo-dT primer (Invitrogen). Final results were normalized with intrinsic GAPDH and PCR Taqman PCR probe in quantity (Applied Biosystems). RT-PCR was performed to determine expression levels of genes of interest. Amplification proceeded for 30-39 cycles. PCR products were separated on agarose gels and visualized by ethidium bromide staining. The primer sets used are shown in Table S1, which is available at .
###end p 46
###begin title 47
ESP preparation and TEM study.
###end title 47
###begin p 48
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 369 370 368 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 472 473 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 633 634 632 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 690 691 689 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 702 704 701 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 722 728 <span type="species:ncbi:9913">bovine</span>
###xml 940 946 <span type="species:ncbi:10090">murine</span>
###xml 970 974 <span type="species:ncbi:10090">mice</span>
Platelets in culture supernatant were gently collected. Acid citrate dextrose solution was added to yield final concentrations of 8.5 mM sodium citrate, 6.5 mM citric acid, and 10.4 mM glucose. The collected fluid was centrifuged at 150 g for 10 min to eliminate large cells (e.g., megakaryocytes). The supernatant was transferred into a new tube, 1 muM prostaglandin E1 and 1 U/ml apyrase were added to prevent platelet activation, and the mixture was centrifuged at 400 g for 10 min to sediment a platelet pellet. The pellet was resuspended in an appropriate volume of modified Tyrode-Hepes buffer, pH 7.4 (10 mM Hepes, 12 mM NaHCO3, 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, and 1 mM MgCl2 without Ca2+), or in 2% fetal bovine serum in PBS. To determine the number of platelets in culture, cells were mixed with True Count Beads (BD Biosciences). To detect ESPs in flow cytometry dot plots, the side scatter and forward scatter gates for murine plasma platelets (from mice aged 8-12 wk) were used. TEM studies were performed by using a JEOL 1200EX transmission electron microscope operating at 80 kV (JOEL). Specimens were treated with a mixture of 0.5% glutaraldehyde and 2% paraformaldehyde, followed by 1% osmium tetroxide for observation.
###end p 48
###begin title 49
Biochemical studies.
###end title 49
###begin p 50
###xml 138 139 138 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
For immunoprecipitation, lysis buffer (2% Triton X-100 or 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 0.5 mM EGTA, 0.5 mM EDTA, 1 mM Na3VO4, 0.5 mM NaF, 0.5 mM PMSF, and 50 mug/ml leupeptin) was used. Separated supernatant in culture at day 12 of culture was immunoprecipitated with anti-GPIbalpha antibody and immunoblotted with anti-GPIbalpha antibody (clone Xia G7).
###end p 50
###begin title 51
Integrin activation and actin cytoskeletal changes.
###end title 51
###begin p 52
###xml 796 797 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 421 426 <span type="species:ncbi:10090">mouse</span>
To investigate integrin alphaIIbbeta3 activation, 50-mul aliquots of ESPs were incubated with APC-conjugated anti-alphaIIb and 200 mug/ml Alexa 488-fibrinogen in the absence or presence of thrombin or ADP for 30 min at room temperature. Binding of Alexa 488-fibrinogen to ESPs was quantified using flow cytometry. Nonspecific binding was determined in the presence of 10 mM EDTA or 20 mug/ml 1B5, a specific inhibitor of mouse alphaIIbbeta3 (provided by B. Coller, The Rockefeller University, New York, NY). Specific binding was defined as total minus nonspecific binding. To investigate outside-in signaling via alphaIIbbeta3, all observations of cytoskeletal changes (morphology of spreading) in ESPs were performed using a confocal microscopic system (TCS SP2; Leica) as described previously (9).
###end p 52
###begin title 53
Flow chamber study.
###end title 53
###begin p 54
###xml 270 278 270 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 634 636 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1026 1028 1020 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1221 1223 1215 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib59">59</xref>
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
###xml 368 373 <span type="species:ncbi:10090">mouse</span>
###xml 431 436 <span type="species:ncbi:10090">mouse</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
To study the effect of inhibition on metalloproteinases, reconstituted whole blood was prepared by combining ESPs and mouse blood. ESPs were generated from ESCs in which the CAG promoter consistently controls Ds-red expression (provided by H. Niwa, RIKEN, Kobe, Japan) (Fig. 5 A). ESPs in which red fluorescent protein was expressed were combined (1:1,000 ratio) with mouse whole blood that had been labeled with mepacrine to mark mouse platelets; the total volume per experiment was 7-8 ml. Washed platelets obtained from mice aged 10-12 wk were stained with 4 mug/ml of PE-labeled anti-alphaIIb antibody (to avoid blocking effect) (42). This whole blood was also obtained from 11-12 C57/BL6 mice aged 10-12 wk per single experiment; argatrovan, an anti-thrombin drug (Mitsubishi Pharma), was added at a final concentration of 100 muM. Samples of the treated blood, containing ESPs, were injected into the chamber with a syringe pump (Harvard Apparatus) at a constant flow rate to achieve high wall shear rates (i.e., 1,500 s-1) on collagen surfaces. Platelet thrombi forming on the collagen surfaces were visualized with an inverted-stage epifluorescence videomicroscope system (DM IRB; Leica) as described previously (59). The microscopic images were digitized online with a photosensitive color CCD camera (L-600; Leica). Image-J software (National Institutes of Health [NIH] Image) was used to quantify the percentages of surfaces covered by platelets.
###end p 54
###begin title 55
Kinetics of residualESPs in vivo after transfusion.
###end title 55
###begin p 56
###xml 136 144 136 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 624 625 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
ESPs were generated from ESCs in which the CAG promoter consistently controls GFP expression (provided by H. Niwa, RIKEN, Kobe, Japan) (Fig. 6 A). ESPs were generated in culture in the absence or presence of metalloproteinase inhibitor. On day 12 of culture, 3 x 106 ESPs were transfused into mice (129Ola strain) in which platelet numbers had been reduced by irradiation (650 cGy) 10 d beforehand. To detect GFP-expressing ESPs at the indicated time points, blood samples were collected with micro-capillaries from the retroorbital venous plexus and stained with APC-conjugated anti-alphaIIb antibody. The percentage of GFP+ ESPs was determined by flow cytometry for each specimen.
###end p 56
###begin title 57
Statistical analysis.
###end title 57
###begin p 58
###xml 101 102 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Differences between experimental and control results (mean +/- SE median) were analyzed by Student's t test. Probability values of P < 0.05 were considered significant.
###end p 58
###begin title 59
Online supplemental material.
###end title 59
###begin p 60
###xml 230 233 230 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 226 233 226 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP9<sup>&#8722;/&#8722;</sup></italic>
###xml 261 264 261 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 257 264 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP9<sup>+/+</sup></italic>
###xml 104 109 <span type="species:ncbi:9606">human</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
Table S1 depicts the primers for Fig. 1 F. Fig. S1 shows the effects of GM6001 on the spreading of aged human platelets on fibrinogen. Fig. S2 shows the platelet number and functions via an integrin bidirectional signaling in MMP9-/- mice and their control MMP9+/+ mice. The online supplemental material is available at .
###end p 60
###begin title 61
Supplementary Material
###end title 61
###begin title 62
[Supplemental Material Index]
###end title 62
###begin p 63
###xml 105 109 <span type="species:ncbi:10090">mice</span>
The authors thank Drs. H. Miyazaki, M. Ogawa, H. Niwa, B. Coller, and Z. Werb for providing reagents and mice. We are also very grateful to H. Tsukui for her excellent help and Drs. A.S. Knisely and M. Mahaut-Smith for manuscript review.
###end p 63
###begin p 64
H. Nishikii, K. Eto, N. Tamura, T. Kanaji, A. Sawaguchi, and S. Goto performed the study. K. Hattori, B. Heissig, and J. Ware provided critical reagents. H. Nishikii and K. Eto designed the study. K. Eto and H. Nakauchi wrote the manuscript.
###end p 64
###begin p 65
This work was supported by grants from the Ministry of Education, Culture, Sport, Science and Technology of Japan (to K. Eto and H. Nakauchi) and by a grant from Vehicle Locomotion Foundation (Tokyo, Japan, to K. Eto and S. Goto).
###end p 65
###begin p 66
The authors have no conflicting financial interests.
###end p 66

